Literature DB >> 2220356

Occurrence of drusen, pigmentary changes and exudative changes in the macula with reference to age-related macular degeneration. An epidemiological study of 1000 aged individuals.

T Vinding1.   

Abstract

Macular changes in 60 to 80-year-old people i.e. drusen (DR), pigmentary changes (PC) and exudative changes (EXC) are assessed by fundoscopy in a random and age stratified population with 924 of the participants examined in both maculae (1848 eyes). DR, PC and EXC were found in 18.4%, 12.9% and 2.1% of all eyes with a rising frequency associated with increasing age. A separation was made between changes implying a visual acuity of 6/9 or less as criteria of age-related macular degeneration (AMD) and age related macular changes without visual impairment (AMCW). The occurrence of DR, PC and EXC from eyes with AMD showed an age related rise which was also found for DR, contrary to PC and EXC deriving from eyes with AMCW. The basic forms of AMD, atrophic and exudative, were represented in 78.6% and 21.4% of individuals or 80.9% and 19.1% of eyes with AMD. The predominant findings in AMD eyes were DR + PC in combination represented in 60.7% of atrophic and 66.8% of exudative AMD eyes, while in atrophic AMCW eyes DR as only finding was leading with 59.2%. It is concluded that in eyes with atrophic macular changes, DR, respectively PC as only finding involves no visual deterioration in 80.6%, respectively 72.6%, while DR + PC in combination, as well as the appearance of EXC, are found to be the most likely expression of AMD as long as a visual impairment of 6/9 or worse is included in the definition of AMD.

Entities:  

Mesh:

Year:  1990        PMID: 2220356     DOI: 10.1111/j.1755-3768.1990.tb01668.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN: 0001-639X


  16 in total

Review 1.  Aging and vision.

Authors:  Cynthia Owsley
Journal:  Vision Res       Date:  2010-10-23       Impact factor: 1.886

Review 2.  Basement membranes and artificial substrates in cell transplantation.

Authors:  Carl Sheridan; Rachel Williams; Ian Grierson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-11-20       Impact factor: 3.117

3.  Macular degeneration: how big is the problem?

Authors:  E Cheraskin
Journal:  J Natl Med Assoc       Date:  1992-10       Impact factor: 1.798

4.  IL-33 is induced by amyloid-β stimulation and regulates inflammatory cytokine production in retinal pigment epithelium cells.

Authors:  Xiao-Cui Liu; Xiao-Fei Liu; Cong-Xiang Jian; Chen-Jun Li; Shou-Zhi He
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

5.  Intravitreal dobesilate in the treatment of choroidal neovascularisation associated with age-related macular degeneration: report of two cases.

Authors:  Pedro Cuevas; Luis Outeiriño; Carlos Azanza; Guillermo Giménez-Gallego
Journal:  BMJ Case Rep       Date:  2012-09-03

Review 6.  Angiotensin II-related hypertension and eye diseases.

Authors:  Pablo Jesus Marin Garcia; Maria Encarna Marin-Castaño
Journal:  World J Cardiol       Date:  2014-09-26

7.  A hapten generated from an oxidation fragment of docosahexaenoic acid is sufficient to initiate age-related macular degeneration.

Authors:  Joe G Hollyfield; Victor L Perez; Robert G Salomon
Journal:  Mol Neurobiol       Date:  2010-03-12       Impact factor: 5.590

8.  NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components.

Authors:  Sarah L Doyle; Matthew Campbell; Ema Ozaki; Robert G Salomon; Andres Mori; Paul F Kenna; Gwyneth Jane Farrar; Anna-Sophia Kiang; Marian M Humphries; Ed C Lavelle; Luke A J O'Neill; Joe G Hollyfield; Peter Humphries
Journal:  Nat Med       Date:  2012-05       Impact factor: 53.440

9.  Pattern electroretinography in senile macular degeneration.

Authors:  D G Sanders; G H Van Lith
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

10.  Colour contrast sensitivity in patients with soft drusen, an early stage of ARM.

Authors:  C Frennesson; U L Nilsson; S E Nilsson
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.